Penile rehabilitation after radical prostatectomy: Where do we stand and where are we going?

被引:73
|
作者
Wang, Run
机构
[1] Univ Texas, Sch Med, Div Urol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源
JOURNAL OF SEXUAL MEDICINE | 2007年 / 4卷 / 04期
关键词
penile rehabilitation; erectile dysfunction; radical prostatectomy;
D O I
10.1111/j.1743-6109.2007.00482.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Postprostatectomy erectile dysfunction (ED) remains a serious quality-of-life issue. Recent advances in the understanding of the mechanism of postprostatectomy ED have stimulated great attention toward penile rehabilitation. Aim. This review presents and analyzes a contemporary series of the recent medical literature pertaining to penile rehabilitation therapy after radical prostatectomy (RP). Main Outcome Measures. The laboratory and clinical studies related to penile rehabilitation are analyzed. The validity of the methodology and the conclusion of the findings from each study are determined. Methods. The published and presented reports dealing with penile rehabilitation following RP in human and cavernous nerve injury in animal models are reviewed. Results. Exciting scientific discoveries have improved our understanding of postprostatectomy ED at the molecular level. The rationale for postprostatectomy penile rehabilitation appears to be logical according to animal studies. However, clinical studies have not consistently replicated the beneficial effects found in the laboratory studies. Currently available clinical studies are flawed due to short-term follow-up, small number of patients in the studies, studies with retrospective nature, or prospective studies without control. Rehabilitation programs are also facing a challenge with the compliance, which is critical for success for any rehabilitation program. At the present time, we do not have concrete evidence to recommend what, when, how long, and how often a particular penile rehabilitative therapy can be used effectively. Conclusions. Large prospective, multicentered, placebo-controlled trials with adequate follow-up are necessary to determine the cost-effective and therapeutic benefits of particular penile rehabilitative therapy or therapies in patients following the treatment of clinically localized prostate cancer. Until such evidence is available, it is difficult to recommend any particular penile rehabilitation program as a standard of practice.
引用
收藏
页码:1085 / 1097
页数:13
相关论文
共 50 条
  • [21] Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going?
    Pendleton, John
    Pisters, Louis L.
    Nakamura, Kogenta
    Anai, Satoshi
    Rosser, Charles J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (01) : 11 - 18
  • [22] 2008 Whitmore Lecture: Radical prostatectomy-where we were and where we are going
    Walsh, Patrick C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (03) : 246 - 250
  • [23] The DO upgrade: where we are and where we are going
    Evans, HG
    NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 2001, 462 (1-2): : 179 - 183
  • [24] Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?
    Peng, Yan
    Yan, Hongxiang
    Mei, Wuxuan
    Zhang, Pengfei
    Zeng, Changchun
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1378 - 1391
  • [25] Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?
    Yan Peng
    Hongxiang Yan
    Wuxuan Mei
    Pengfei Zhang
    Changchun Zeng
    Current Treatment Options in Oncology, 2023, 24 : 1378 - 1391
  • [26] Neutrino properties and neutrino astronomy: Where do we stand, where are we going? - Experiments
    Spiro, M
    Lachenmaier, T
    NUCLEAR PHYSICS B-PROCEEDINGS SUPPLEMENTS, 2003, 118 : 413 - 424
  • [27] TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
    Zattra, Edoardo
    Stan, Roxana
    Russo, Irene
    Lo Nigro, Alessandro
    Peserico, Andrea
    Alaibac, Mauro
    IMMUNOTHERAPY, 2013, 5 (08) : 791 - 794
  • [28] Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?
    Snijders, Malou L. H.
    Varol, Hilal
    van der Zwan, Marieke
    Becker, Jan U.
    Hesselink, Dennis A.
    Baan, Carla C.
    von der Thusen, Jan H.
    Clahsen-van Groningen, Marian C.
    TRANSPLANTATION, 2020, 104 (12) : 2478 - 2486
  • [29] Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
    Harari, Sergio
    Humbert, Marc
    Blasi, Francesco
    Collard, Harold R.
    Matucci-Cerinic, Marco
    Simonneau, Gerald
    Vancheri, Carlo
    Wells, Athol U.
    Cottin, Vincent
    EUROPEAN RESPIRATORY REVIEW, 2015, 24 (137): : 375 - 377
  • [30] Immunosuppressive treatment for refractory ulcerative colitis - where do we stand and where are we going?
    Scholmerich, J
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (09) : 842 - 849